Crossmark Global Holdings Inc. Increases Stock Position in Abbott Laboratories $ABT

Crossmark Global Holdings Inc. increased its stake in Abbott Laboratories (NYSE:ABT) by 4.3% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 300,773 shares of the healthcare product maker’s stock after purchasing an additional 12,373 shares during the quarter. Abbott Laboratories accounts for 0.6% of Crossmark Global Holdings Inc.’s portfolio, making the stock its 21st largest position. Crossmark Global Holdings Inc.’s holdings in Abbott Laboratories were worth $40,286,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. KCM Investment Advisors LLC lifted its holdings in shares of Abbott Laboratories by 1.2% during the 3rd quarter. KCM Investment Advisors LLC now owns 148,678 shares of the healthcare product maker’s stock valued at $19,914,000 after buying an additional 1,732 shares during the period. Advisory Alpha LLC increased its position in Abbott Laboratories by 3.8% during the third quarter. Advisory Alpha LLC now owns 7,533 shares of the healthcare product maker’s stock valued at $1,002,000 after acquiring an additional 273 shares during the last quarter. NewSquare Capital LLC lifted its holdings in Abbott Laboratories by 48.4% in the third quarter. NewSquare Capital LLC now owns 1,644 shares of the healthcare product maker’s stock valued at $220,000 after acquiring an additional 536 shares during the period. IFG Advisory LLC boosted its position in Abbott Laboratories by 7.9% in the third quarter. IFG Advisory LLC now owns 37,748 shares of the healthcare product maker’s stock worth $5,056,000 after purchasing an additional 2,761 shares during the last quarter. Finally, Diversified Portfolios Inc. grew its stake in shares of Abbott Laboratories by 5.6% during the 3rd quarter. Diversified Portfolios Inc. now owns 4,328 shares of the healthcare product maker’s stock valued at $580,000 after purchasing an additional 230 shares during the period. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Abbott Laboratories

In other Abbott Laboratories news, SVP Eric Shroff sold 709 shares of the company’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $81,946.22. Following the transaction, the senior vice president owned 39,164 shares of the company’s stock, valued at $4,526,575.12. This represents a 1.78% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Daniel J. Starks bought 10,000 shares of the firm’s stock in a transaction dated Wednesday, February 4th. The shares were acquired at an average price of $108.73 per share, with a total value of $1,087,300.00. Following the completion of the transaction, the director owned 6,738,817 shares of the company’s stock, valued at approximately $732,711,572.41. The trade was a 0.15% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have sold 3,055 shares of company stock worth $353,097 over the last quarter. 0.46% of the stock is owned by insiders.

Analysts Set New Price Targets

Several analysts recently issued reports on the stock. Raymond James Financial cut their target price on shares of Abbott Laboratories from $146.00 to $130.00 and set an “outperform” rating for the company in a research report on Friday, January 23rd. Evercore cut their price objective on shares of Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating for the company in a research report on Friday, January 23rd. Citigroup decreased their target price on Abbott Laboratories from $155.00 to $140.00 and set a “buy” rating on the stock in a report on Friday, January 23rd. Oppenheimer cut their price target on Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating for the company in a report on Friday, January 23rd. Finally, Sanford C. Bernstein reduced their price target on Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating for the company in a research report on Friday, January 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $137.05.

Abbott Laboratories News Roundup

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: FDA approved Abbott’s redesigned CardioMEMS Hero remote heart‑failure monitor — a smaller, lighter reader that could improve clinician workflows and patient adoption, supporting long‑term device revenue growth. How FDA Approval of CardioMEMS Hero Remote Monitor At Abbott (ABT) Has Changed Its Investment Story
• Neutral Sentiment: Several insiders (senior VPs/EVPs) disclosed small sales of ABT shares on Mar. 2 — amounts are modest relative to their remaining holdings and likely represent routine portfolio management rather than a clear signal. Abbott Laboratories Insider Selling
• Neutral Sentiment: Elevated investor attention — Zacks flags ABT as drawing interest, which can amplify moves in either direction but doesn’t by itself change fundamentals. Abbott Laboratories (ABT) is Attracting Investor Attention
• Negative Sentiment: Revenue miss in the latest quarter (reported $11.46B vs. consensus ≈ $11.8B) — EPS met estimates but the top‑line shortfall and softer near‑term trends have left analysts cautious and pressured the stock. Abbott (ABT) Stock Sinks As Market Gains: Here’s Why
• Negative Sentiment: Legal risk: Abbott is set to face trial over claims that a premature‑infant formula caused a deadly disease — a high‑visibility lawsuit that could create financial and reputational downside depending on outcomes or settlements. Abbott set to face trial over claims premature infant formula caused deadly disease

Abbott Laboratories Stock Performance

NYSE ABT opened at $113.09 on Thursday. The business’s 50 day moving average price is $116.67 and its 200-day moving average price is $124.91. Abbott Laboratories has a fifty-two week low of $105.27 and a fifty-two week high of $139.15. The company has a market cap of $196.51 billion, a P/E ratio of 30.40, a P/E/G ratio of 1.81 and a beta of 0.74. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.18 and a current ratio of 1.58.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, hitting the consensus estimate of $1.50. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. The company had revenue of $11.46 billion during the quarter, compared to analyst estimates of $11.80 billion. During the same period in the previous year, the firm earned $1.34 earnings per share. Abbott Laboratories’s quarterly revenue was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Sell-side analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be issued a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 2.2%. The ex-dividend date is Wednesday, April 15th. Abbott Laboratories’s dividend payout ratio is presently 67.74%.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.